← Leaderboards
Paul S Shapiro
University Of Maryland Baltimore
$3,183,117
Attributed
$4,895,562
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,895,562 · 6
By mechanism
R01$2,806,126 · 2
R61$1,020,046 · 1
R21$707,460 · 2
R33$361,930 · 1
Top collaborators
- Deepak A Deshpande5 shared
- Jeffrey D Hasday5 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- George G Rodney$5,748,402
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionProteinsLeadPathogenesisSignal PathwayMitogen-Activated Protein KinasesPhosphorylationDockingNovel TherapeuticsCell ProliferationInhibitor/AntagonistKinase InhibitorComplexTranscription FactorDrug DesignBinding SitesComputer AssistedFamilySiteCellsToxic EffectPlayPathway InteractionsExtracellular Signal Regulated Kinases
Grant awards (20)
Optimizing function-selective ERK1/2 inhibitors for reducing AP-1-mediated airway pathology in asthma.$361,930
R33 · FY2025 · HL · contact PI
Optimizing function-selective ERK1/2 inhibitors for reducing AP-1-mediated airway pathology in asthma.$495,069
R61 · FY2024 · HL · contact PI
Optimizing function-selective ERK1/2 inhibitors for reducing AP-1-mediated airway pathology in asthma.$524,977
R61 · FY2023 · HL · contact PI
Evaluation of novel substrate specific inhibitors of ERK1/2 in the treatment of asthma$194,087
R21 · FY2017 · AI · contact PI
p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injury$383,750
R01 · FY2016 · HL
Evaluation of novel substrate specific inhibitors of ERK1/2 in the treatment of asthma$246,073
R21 · FY2016 · AI · contact PI
p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injury$377,993
R01 · FY2015 · HL
p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injury$376,075
R01 · FY2014 · HL
p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injury$99,606
R01 · FY2014 · HL
p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injury$365,330
R01 · FY2013 · HL
Substrate specific ERK docking domain inhibitors$230,349
R01 · FY2010 · CA · contact PI
Substrate specific ERK docking domain inhibitors$230,349
R01 · FY2009 · CA · contact PI
Substrate specific ERK docking domain inhibitors$47,373
R01 · FY2009 · CA · contact PI
Substrate specific ERK docking domain inhibitors$204,755
R01 · FY2008 · CA · contact PI
Substrate specific ERK docking domain inhibitors$46,170
R01 · FY2008 · CA · contact PI
Substrate specific ERK docking domain inhibitors$204,755
R01 · FY2007 · CA · contact PI
Substrate specific ERK docking domain inhibitors$28,751
R01 · FY2007 · CA · contact PI
Substrate specific ERK docking domain inhibitors$210,870
R01 · FY2006 · CA · contact PI
Development of ERK docking domain inhibitors$133,650
R21 · FY2005 · CA
Development of ERK docking domain inhibitors$133,650
R21 · FY2004 · CA